CIPLA Q2: INDIA BRANDED BUSINESS GROWS 15%; US REVENUE IMPROVES TO $172 MN, KEY FDA APPROVALS SUPPORT GROWTH

• India Branded Business: Delivered 15% growth, supported by strong double-digit growth across Respiratory, Urology, Cardiac, Anti-diabetes and Dermatology therapies • Trade Generics: Recorded strong double-digit QoQ growth, supported by 15+ new product launches during Q2 • Consumer Health: Nicotex, Omnigel and Cipladine maintained leadership positions in their respective market segments • North America Revenue: At $172 Mn, improving by $10 Mn QoQ • Albuterol Market Share: Ranked No. 1 in the overall US Albuterol MDI market with 22% market share • USFDA Approval: Received FDA approval for generic Advair Diskus, marking Cipla's first dry powder inhaler approval from its US manufacturing network • Biosimilar Expansion: Entered exclusive partnership with Qilu Pharmaceutical to commercialise a Keytruda biosimilar in the US • South Africa Business: Private market secondary growth at 6.5% versus industry growth of 5%; prescription business maintained No. 2 position • Emerging Markets & Europe: Revenue stood at $101 Mn amid geopolitical uncertainties and market-specific challenges • Growth Strategy: Focus on complex respiratory products, oncology biosimilars, new product launches and cost efficiency to support future growth

CIPLA LTD

← Back to feed